STAMBP Accelerates Progression and Tamoxifen Resistance of Breast Cancer Through Deubiquitinating ERα.

Zhihuai Wang, Likai Gu, Mei Yang, Yi Zhou, Xihu Qin, Chen Xiong

Abstract read

In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhihuai WangDepartment of General Surgery, The Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.

Likai GuChangzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.

Mei YangChangzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.

Yi ZhouChangzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.

Xihu QinChangzhou Medical Center, Nanjing Medical University, Changzhou 213000, China.

Chen XiongClinical Medical College, Shandong University, Jinan 250012, China.ORCID 0009-0008-7842-5283

Funding

Xihu Qin 2022CZZY005Xihu Qin 2024CZBJ018Xihu Qin CZKYCMC2024PY24

6 · The paper itself

Abstract

Breast cancer (BRCA) remains a global health burden, with endocrine-resistant ER-positive BRCA posing therapeutic challenges. This study investigates STAMBP's role in breast cancer progression and evaluates its potential as a therapeutic target. Through siRNA library screening in ER-positive cell lines, we identified STAMBP as a key regulator of ERα signaling and observed its upregulation in BRCA samples. (fold changes > 2, sample sizes = 30,

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmEstrogen Receptor alphaTamoxifenAnimalsCell Line, TumorCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansPrognosisSignal TransductionUbiquitinationESR1 protein, humanEstrogen Receptor alphaTamoxifenbreast cancerdeubiquitinationendocrine therapyestrogen receptor αSTAMBP

Identifiers

PMID41301420

DOI10.3390/biom15111502

PMCPMC12650272

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.